CCR2 and ovarian cancer: A high M1/M2 ratio correlates with better prognosis and platinum sensitivity in ovarian cancer patients, while ABBV-075’s ability to downregulate CCR2 expression in macrophages disrupts the MSMP/CCR2-mediated adaptive resistance to AVA.